. 2019 Aug 25;60(2):188–197. doi: 10.1002/jcph.1513

Table 1.

Overview of the Studies Included in the Analysis

Study	Population	N	Study Design Pharmacokinetic Sampling/Subject	Active Treatment	Dose(s)^a	Reference
1	Healthy subjects	56	Single‐dose, randomized, placebo‐controlled	Upadacitinib	1, 3, 6, 12, 24, 36, 48 mg	Mohamed et al²⁰
2, Part 1	Healthy subjects	44	Multiple‐dose, randomized, placebo‐controlled	Upadacitinib	3, 6, 12, 24 mg BID	Mohamed et al²⁰
2, Part 2	Subjects with mild to moderate RA	14	Multiple dose, randomized, placebo‐controlled	Upadacitinib	6, 12, 24 mg BID	Mohamed et al²⁰
2, Part 3	Healthy subjects	9	Multiple dose, open‐label	Tofacitinib	5 mg BID	–

BID, twice daily; RA, rheumatoid arthritis.

^aUpadacitinib and tofacitinib were administered in the study as immediate‐release formulations.